Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-02-11 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2019年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "厦门艾德生物医药科技股份有限公司 2019 年限制性股票激励计划（草案）" which translates to "Xiamen Adicon Biomedicine Technology Co., Ltd. 2019 Restricted Stock Incentive Plan (Draft)". It is a detailed draft plan for a restricted stock incentive program, including legal basis, stock quantities, allocation, vesting conditions, performance targets, and management structure. The document is lengthy (15,000 characters) and contains comprehensive details about the stock incentive plan, its terms, conditions, and implementation procedures. It is not an announcement of a report, nor a financial statement or earnings release. It is a detailed plan related to management compensation and incentives through stock awards. This fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans. Therefore, the document is classified as Remuneration Information (DEF 14A).
2019-02-11 Chinese
关于部分持股5%以上股东减持股份的进展公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the progress of shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the methods of reduction (block trades and centralized bidding), dates, prices, and the shareholder's holdings before and after the reduction. It also confirms compliance with relevant securities laws and regulations. There is no financial performance data, no management discussion, no earnings information, no audit or legal proceedings details, and no mention of a report being attached or published. This type of document fits the category of Major Shareholding Notification, which covers notifications of changes in significant share ownership levels crossing thresholds.
2019-02-11 Chinese
关于持股5%以上股东减持股份比例达到1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the number of shares sold, the dates, prices, and the shareholder's holdings before and after the reduction. It explicitly states it is a disclosure about a shareholder's shareholding change and reduction, with no financial statements or company performance data included. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2019-01-29 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the purchase and redemption of low-risk financial products using temporarily idle raised funds, including amounts, terms, and expected yields. The document includes tables of financial product transactions and risk control measures. It is an update on the company's financing activities related to the use of raised funds, not a full financial report or earnings release. The document length is about 5,245 characters, which is sufficient for a detailed announcement but not a full annual or interim report. The content focuses on capital management and financing activities, specifically the use of idle raised funds for cash management. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-01-24 Chinese
2018年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2018 annual performance forecast (业绩预告) from a company, providing estimated financial results for the full year 2018. It explicitly states that the forecast is unaudited and preliminary, with actual audited data to be disclosed in the 2018 annual report. The document is short (994 characters) and serves as a performance preview rather than a full financial report. It does not contain actual financial statements or detailed analysis, only estimated results and explanations. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2018
2019-01-08 Chinese
关于特定股东股份减持计划时间过半未减持公司股份的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company regarding the status of a specific shareholder's planned reduction of shares. It details that the shareholder has not yet reduced any shares and provides assurances about compliance with relevant securities laws and regulations. The document does not contain financial statements, audit information, or detailed financial results. It is focused on shareholding changes by a significant shareholder but does not indicate a change in control or a new major shareholding notification crossing thresholds. The content fits best with a Transaction in Own Shares (POS) or Share Issue/Capital Change (SHA) category. However, since it concerns a shareholder's planned reduction (sale) of shares rather than issuance or capital increase, it aligns with Transaction in Own Shares (POS), which covers share repurchase or issuance activities by the company or related share transactions. Given the shareholder is not the controlling shareholder and the announcement is about a reduction plan, the best fit is POS. Confidence is high due to clear mention of share reduction plans and compliance statements related to share transactions.
2019-01-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.